Pair page
Hexarelin with Testosterone
Mechanism-tag overlap and published literature for Hexarelin and Testosterone, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ghrpgrowth-hormone-releasing-peptide
androgenprimary-male-sex-hormone
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Hexarelin and Testosterone have published these mechanism-level observations. Not a co-administration recommendation.
Full-axis protocols sometimes include hexarelin short-courses alongside TRT for body composition. Requires clinician oversight and monitoring of GH axis, androgen axis, and adrenal markers.
Quick facts
Hexarelin
Testosterone
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2004 | Hexarelin | Frieboes RM, Antonijevic IA, Held K, Murck H, Pollmächer T, Schuld A, Steiger A. Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Psychoneuroendocrinology. 2004;29(6):728-739. PMID: 15177700. PMID 15177700 | human study |
| 2003 | Hexarelin | Broglio F, Gottero C, Benso A, Prodam F, Destefanis S, Gauna C, Maccario M, Deghenghi R, van der Lely AJ, Ghigo E. Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. J Clin Endocrinol Metab. 2003;88(9):4268-4272. PM… PMID 12970297 | human study |
| 1999 | Hexarelin | Popovic V, Damjanovic S, Micic D, Djurovic M, Petakov M, Dieguez C, Casanueva FF. Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test. J Clin Endocrinol… PMID 10443652 | human study |
| 1999 | Hexarelin | Giordano R, Picu A, Broglio F, Bonelli L, Baldi M, Berardelli R, Ghigo E, Arvat E. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486. J Endocrinol Invest. 1999;22(9):617-622. PMID: 10516483. PMID 10516483 | human study |
| 1994 | Hexarelin | Imbimbo BP, Mant T, Edwards M, Amin D, Dalton N, Boutignon F, Lenaerts V, Wüthrich P, Deghenghi R. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol. 1994;46(5):421-425. PMID: 7957536. PMID 7957536 | human study |
| 2000 | Hexarelin | Torsello A, Locatelli V, Melis MR, Succu S, Spano MS, Deghenghi R, Müller EE, Argiolas A. Differential orexigenic effects of hexarelin and its analogs in the rat hypothalamus: indication for multiple growth hormone secretagogue receptor subtypes. Neuroendocrinology. 2000;72(6):3… PMID 11146416 | preclinical, in vivo |
| 1999 | Hexarelin | Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, Deghenghi R, Müller EE, Berti F. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-4031. PMID: 10465271. PMID 10465271 | preclinical, in vivo |
| 2026 | Hexarelin | WADA. 2026 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. | regulatory / registry |
| 2004 | Hexarelin | Demers A, McNicoll N, Febbraio M, Servant M, Marleau S, Silverstein R, Ong H. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J. 2004;382(Pt 2):417-424. PMID: 15285719. PMID 15285719 | research article |
| 2002 | Hexarelin | Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849. PMID: 11988484. PMID 11988484 | research article |
| 2000 | Hexarelin | Chen C. Growth hormone secretagogue actions on the pituitary gland: multiple receptors for multiple ligands? Clin Exp Pharmacol Physiol. 2000;27(5-6):323-329. PMID: 10779119. PMID 10779119 | research article |
| 1999 | Hexarelin | Imbimbo BP, Greco F, Marchiaro F, Mantovani V, Rocchi R, Ongini E. The effects of dose, nutrition, and age on hexarelin-induced anterior pituitary hormone secretion in adult patients on maintenance hemodialysis. Nephron. 1999;82(2):147-156. PMID: 10199757. PMID 10199757 | research article |
| 2007 | Testosterone | Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis. Mayo Clin Proc. 2007;82(1):29-39. PMID: 17285783. PMID 17285783 | systematic review |
| 2015 | Testosterone | Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med. 2015;3(4):269-279. PMID: 26797061. PMC4721027. PMID 26797061 | human trial, Phase 2 |
| 2018 | Testosterone | Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364. PMID 29562364 | human study |
| 2013 | Testosterone | Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. PMID: 24024838. PMID 24024838 | human study |
| 2008 | Testosterone | Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919. PMID: 18160461. PMID 18160461 | human study |
| 2001 | Testosterone | Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724-731. PMID: 11158037. PMID 11158037 | human study |
| 2025 | Testosterone | WADA. 2025 Prohibited List. Section S1 — Anabolic Agents. World Anti-Doping Agency. | regulatory / registry |
| 2023 | Testosterone | Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE; TRAVERSE Stu… PMID 37326322 | research article |
| 2018 | Testosterone | Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. PMID: 29601923. PMID 29601923 | research article |
| 2016 | Testosterone | Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. PMID: 26886521. PMID 26886521 | research article |
| 2016 | Testosterone | Morgentaler A, Zitzmann M, Traish AM, Fox AW, Jones TH, Maggi M, Arver S, Aversa A, Chan JC, Dobs AS, Hackett GI, Hellstrom WJ, Lim P, Lunenfeld B, Mskhalaya G, Schulman CC, Torres LO. Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Con… PMID 27313122 | research article |
| 2016 | Testosterone | Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016;5(6):834-843. PMID: 28078214. PMID 28078214 | research article |
Related pair pages
More research context
Frequently asked
Have Hexarelin and Testosterone been studied together?
Researchers have published mechanistic-level co-administration discussion of Hexarelin and Testosterone. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Hexarelin and Testosterone share?
Hexarelin and Testosterone do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Hexarelin and Testosterone?
Hexarelin: Not approved; Category 2. Testosterone: Approved (multiple formulations). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Hexarelin and Testosterone?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Hexarelin profile and the Testosterone profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026